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jejuni
Abstract
Objectives
CmeABC is a resistance-nodulation-cell division (RND)-type multidrug efflux pump conferring resistance to
clinically important antibiotics in Campylobacter. This study aimed to identify the optimal target sites for the
inhibition of CmeABC with antisense peptide nucleic acid (PNA).
Methods
Eighteen PNAs were designed to bind to the translational initiation regions of cmeABC, spanning the
ribosome-binding site (RBS) and the start codon of the cmeABC genes. Campylobacter jejuni was treated with
CmeABC-specific PNAs (CmeABC-PNAs) at various concentrations and subjected to western blotting to
measure changes in the level of CmeABC expression. The MICs of ciprofloxacin and erythromycin were
measured to evaluate the impact of CmeABC knockdown on antibiotic susceptibility.
Results
While antisense PNA significantly affected CmeA and CmeB expression, interestingly, CmeC expression was
not altered by any of the CmeC-PNAs used in this study. A CmeA-PNA targeting the RBS of cmeA and its
upstream region reduced CmeA expression most efficiently, and CmeB expression was most significantly
decreased by PNA binding to the RBS of cmeB and its downstream region. CmeA- and CmeB-PNAs
increased the susceptibility of C. jejuni to ciprofloxacin and erythromycin in proportion to the inhibition
levels observed in western blotting.
Conclusions
The cmeA gene is the best target to knockdown CmeABC with antisense PNA. The RBS is the major target for
the PNA-mediated antisense inhibition of CmeABC. However, regions in its vicinity also significantly
influence the effectiveness of the PNA-based knockdown of CmeABC.
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Objectives: CmeABC is a resistance-nodulation-cell division (RND)-type multidrug efflux pump conferring resist-
ance to clinically important antibiotics in Campylobacter. This study aimed to identify the optimal target sites
for the inhibition of CmeABCwith antisense peptide nucleic acid (PNA).
Methods:EighteenPNAsweredesigned tobind to the translational initiation regionsof cmeABC, spanning the ribo-
some-binding site (RBS) and the start codonof the cmeABCgenes.Campylobacter jejuniwastreatedwithCmeABC-
specific PNAs (CmeABC-PNAs) at various concentrations and subjected towestern blotting tomeasure changes in
the level of CmeABCexpression. TheMICsof ciprofloxacinanderythromycinweremeasured toevaluate the impact
of CmeABC knockdown on antibiotic susceptibility.
Results: While antisense PNA significantly affected CmeA and CmeB expression, interestingly, CmeC expression
was not altered by any of the CmeC-PNAs used in this study. A CmeA-PNA targeting the RBS of cmeA and its up-
stream region reduced CmeA expressionmost efficiently, and CmeB expression wasmost significantly decreased
by PNAbinding to the RBS of cmeB and its downstream region. CmeA- and CmeB-PNAs increased the susceptibility
of C. jejuni to ciprofloxacin and erythromycin in proportion to the inhibition levels observed in western blotting.
Conclusions: The cmeA gene is the best target to knockdown CmeABC with antisense PNA. The RBS is the major
target for the PNA-mediated antisense inhibition of CmeABC. However, regions in its vicinity also significantly
influence the effectiveness of the PNA-based knockdown of CmeABC.
Keywords: efflux pump inhibitors, fluoroquinolones, macrolides
Introduction
Campylobacter jejuni is a leading foodborne pathogen resulting in
400 million–500 million cases of human infection around the
world annually.1 C. jejuni infection is usually self-limiting and
does not require antibiotic treatment; however, antibiotics are pre-
scribed for severe cases or in immunocompromised patients.2 The
drugs of choice for the treatment of human campylobacteriosis
include fluoroquinolones and macrolides, but C. jejuni has devel-
oped increasing resistance to these clinically important antibiotics,
particularly fluoroquinolones.3
Drug efflux pumps mediate the extrusion of structurally unre-
lated antibiotics out of the cell and are considered to be a major
mechanism responsible for multidrug resistance.4 To potentiate
existing antibiotics and control antibiotic resistance associated
with drug efflux pumps, numerous studies have been reported to
develop efflux pump inhibitors.5 However, inhibitors of prokaryotic
efflux pumps can also interfere with eukaryotic efflux systems,
resulting in toxicity problems, and this is considered to be a
major barrier in the development of efflux pump inhibitors.5
InCampylobacter, CmeABC is a key resistancedeterminant that
confers both intrinsic and acquired resistance to clinically import-
ant antibiotics.6,7 In addition, CmeABC significantly affects the
ability of C. jejuni to colonize chicken intestines due to its import-
ance in resistance to bile salts.8 CmeABC is a resistance-
nodulation-cell division (RND)-type efflux pump consisting of
three protein components located in the inner membrane
(CmeB), periplasm (CmeA) and outer membrane (CmeC), which
are encoded by the polycistronic cmeABC operon.6 In our previous
report, we demonstrated that an antisense peptide nucleic acid
(PNA) targeting CmeA sensitized C. jejuni to ciprofloxacin and
erythromycin.9 However, the targets for antisense PNA have not
been optimized to maximize the susceptibility of C. jejuni to anti-
biotics by CmeABC knockdown. In this study, we identified the
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optimal target sites in cmeABC that are most susceptible to the
inhibition of antisense CmeABC-specific PNAs (CmeABC-PNAs).
Materials and methods
Bacterial strains and CmeABC-PNAs
C. jejuni NCTC 11168 was the first Campylobacter to have its genome
sequenced,10 and was used throughout this study. C. jejuni was grown at
428C with Mueller–Hinton (MH) medium (Oxoid) in microaerobic conditions
(5% O2, 85% N2 and 10% CO2). CmeABC-PNAs were designed based on the
genomesequenceofC. jejuniNCTC11168,10 andwere commerciallysynthe-
sized by Panagene (Daejeon, South Korea; Table 1). To improve antisense
potency, CmeABC-PNAs were conjugated with the cell-permeabilizing
peptide KFFKFFKFFF, as described elsewhere.11
PNA treatment and western blot analysis
C. jejuni NCTC 11168 was grown overnight on MH agar plates and used to
prepare bacterial suspensions in MH broth to an optical density at 600 nm
of 0.05–0.07. Broth cultures of C. jejuni were grown in the presence of
various concentrations of CmeABC-PNAs for 7 h with shaking at 200 rpm.
SDS-PAGE was carried out using a 10% polyacrylamide gel for CmeA in Tris-
Tricine buffer and CmeC in Tris-Glycine buffer, and a 6% polyacrylamide gel
for CmeB in Tris-Glycine buffer. Western blot analysis was performed using
polyclonalantibodiesagainstCmeA,CmeBorCmeCasdescribedpreviously.6
Determination of C. jejuni susceptibility to ciprofloxacin
The MICs of ciprofloxacin (Enzo Life Sciences, USA) and erythromycin
(Sigma, USA) were measured with a microtitre broth dilution method in
the presence or absence of CmeABC-PNAs as previously described.9
Results
DNA sequence analysis of translation initiation regions of
CmeABC in C. jejuni and Campylobacter coli
PNA-mediated gene knockdown is based on blocking translation
initiation in both eukaryotes and prokaryotes.12 The start codon
regions, including the ribosome-binding sites (RBSs), are known
to bemost susceptible to antisense inhibition by PNA in Escherichia
coli.13 To design PNAs targeting cmeABC, we first performed a DNA
sequenceanalysis of the translational initiation regionsof cmeABC.
Since C. jejuni and C. coli are responsible for.95% of human cam-
pylobacteriosis, C. jejuni in particular accounting for .92% of
cases,14,15 the sequence analysis focused on the two Campylobac-
ter specieswhose genome sequences are available in theGenBank
sequence database. Overall, the translation initiation regions of
cmeABC are well conserved in both species (Figure 1). C. jejuni
doylei has one nucleotide change from C to T at a point 2 bp
upstream of the cmeA start codon (Figure 1a), and C. jejuni
ICDCCJ07001 showed a nucleotide change from C to T at a point
7 bp upstream of the cmeB start codon (Figure 1b). However, all
otherC. jejuni strains showed identical sequences in the translation
initiation regions of cmeABC (Figure 1). Relatively high sequence
variation was observed between C. jejuni and C. coli in the transla-
tion initiation region of cmeA (Figure 1a), suggesting that species-
specific PNAs may be required for the effective inhibition of
CmeABC.
Knockdown efficiency of CmeABC-PNAs
Eighteen PNAswere designed to bind to various regions involved in
the translation initiation of cmeA, cmeB and cmeC, primarily tar-
geting either the RBS or the start codon (Figure 2). Since it has
been reported that, due to cell permeability, a 12-mer PNAexhibits
better knockdown efficiency than longer PNAs,11 we also designed
12-mer PNAs in this study. CmeA-PNAs 1, 4 and 5 significantly
reduced CmeA expression at 1 mM, and CmeA-PNA1 further inhib-
ited CmeA expression substantially even at 0.5 mM (Figure 3a).
Among the three CmeA-PNAs (1, 2 and 3) binding to the RBS of
cmeA, CmeA-PNA1 notably inhibited CmeA expression, while the
effect of CmeA-PNAs 2 and 3 in CmeA knockdown was not signifi-
cant (Figure 3a). Three CmeA-PNAs (4, 5 and 6) bind to the start
codon of cmeA (Figure 2a). Treatment with 1 mM CmeA-PNAs 4
and5 resulted in significant reductions in the level of CmeAexpres-
sion (Figure3a); however, CmeA-PNA6had little effectonCmeAex-
pression (Figure 3a). Among the six CmeA-PNAs, CmeA-PNA1
showed the best efficacy in CmeA knockdown (Figure 3a).
CmeB-PNAs 1, 2 and 3 bind to the RBS of cmeB (Figure 2b). Com-
pared with CmeB-PNAs 1 and 2, CmeB-PNA3, which binds to the
RBS and its downstream region, was most effective in inhibiting
CmeB expression (Figure 3b). Interestingly, CmeC expression was
notaffectedbyanyof the six CmeC-PNAsevenathigh PNAconcen-
trations, such as 4 mM (Figure 3c). Since CmeA-PNA1 and
CmeB-PNA3were most effective in inhibiting CmeA and CmeB, re-
spectively, their knockdownefficiencywas further testedbyexpos-
ing C. jejuni to various concentrations of PNA. CmeA-PNA1 and
CmeB-PNA3 demonstrated obvious knockdown efficacy in a
concentration-dependent manner (Figure 4).
C. jejuni susceptibility to ciprofloxacin and erythromycin
following treatment with CmeABC-PNAs
To evaluate the effect of CmeABC knockdownonantibiotic suscep-
tibility, we measured the MICs of ciprofloxacin and erythromycin
after PNA treatment because they are clinically important and
known substrates of the CmeABC efflux pump.3,6 The changes in
MICwere proportional to the levels of CmeABC inhibition observed
Table 1. CmeABC-PNAs used in this study
PNA Sequence (NC)
CmeA-PNA1 KFFKFFKFFK-TGCCTTGAAAAA
CmeA-PNA2 KFFKFFKFFK-TTTTGCCTTGAA
CmeA-PNA3 KFFKFFKFFK-TGGTTTTGCCTT
CmeA-PNA4 KFFKFFKFFK-TCATGGTTTTGC
CmeA-PNA5 KFFKFFKFFK-ATTTCATGGTTT
CmeA-PNA6 KFFKFFKFFK-AATAATTTCATG
CmeB-PNA1 KFFKFFKFFK-CTCCAATTTCTT
CmeB-PNA2 KFFKFFKFFK-GTGCTCCAATTT
CmeB-PNA3 KFFKFFKFFK-ATTGTGCTCCAA
CmeB-PNA4 KFFKFFKFFK-ATTATTGTGCTC
CmeB-PNA5 KFFKFFKFFK-AAAACATTATTG
CmeB-PNA6 KFFKFFKFFK-TTAGAAAACATT
CmeC-PNA1 KFFKFFKFFK-ACCTCTTTTTTT
CmeC-PNA2 KFFKFFKFFK-TTACCTCTTTTT
CmeC-PNA3 KFFKFFKFFK-ACCTTACCTCTT
CmeC-PNA4 KFFKFFKFFK-ATGAACCTTACC
CmeC-PNA5 KFFKFFKFFK-TATTCATGAACC
CmeC-PNA6 KFFKFFKFFK-ATTTTATTCATG
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by western blotting. Compared with PNAs targeting CmeB, most
CmeA-PNAs rendered C. jejuni highly susceptible to ciprofloxacin
and erythromycin (Table 2). In particular, CmeA-PNA1 decreased
the MICs of ciprofloxacin and erythromycin 4-fold even at 0.5 mM
(Table 2). CmeB-PNAs required higher doses than CmeA-PNAs to
achieve similar MIC changes (Table 2). Consistent with the results
(a)
(b)
(c)
Figure 1. Multiple alignment of the translation initiation regions of cmeA (a), cmeB (b) and cmeC (c). TheC. jejuniand C. coliDNAsequences available in the
GenBankdatabasewereused for theanalysis. Start codonsareshown inboldandRBSsareunderlined.GenBankaccessionnumbersareAL111168 (C. jejuni
NCTC11168),CP001876 (C. jejuni IA3902), CP000814 (C. jejuni81116), CP000538 (C. jejuni81_176),NC_003912 (C. jejuniRM1221), CP001960 (C. jejuniS3),
FJ797669 (C. jejuni S3B), CP001900 (C. jejuni M1), CP002029 (C. jejuni ICDCCJ07001), CP000768 (C. jejuni doylei 269.97), DQ333454 (C. jejuni 154KU),
AY598796 (C. coli CIT382), FJ797671 (C. coli 993868) and FJ797673 (C. coli TF1_13). The alignment was performed using ClustalW2.
Antisense PNA inhibition of CmeABC
377
JAC
Downloaded from https://academic.oup.com/jac/article-abstract/69/2/375/714944/Target-optimization-for-peptide-nucleic-acid-PNA
by 04860000 user
on 15 September 2017
of western blotting, CmeC-PNAs did not affect the antimicrobial
susceptibility of C. jejuni (data not shown).
Discussion
In this study, we optimized the antisense inhibition of CmeABC by
using 18 PNAs targeting the translation initiation regions of
cmeABC. The cmeA gene is the first gene in the cmeABC operon
and was the best target for the PNA-mediated knockdown of
CmeABC (Figure 3 and Table 2). Interestingly, CmeC expression
was not altered by antisense PNA even at high doses (Figure 3c),
although CmeC-PNAs were extensively designed to span various
regions associated with translational initiation (Figure 2c). Treat-
mentwith antisense PNAs targetingCmeAandCmeBsubstantially
increased the susceptibility of C. jejuni to ciprofloxacin and erythro-
mycin (Table 2). Consistentwith the observations from thewestern
blot analysis,mostCmeA-PNAssignificantly reduced theMIC levels
(Table 2).
The inhibition efficiency of antisense PNA targeting the cmeABC
operon was highest for cmeA, moderate for cmeB, and low for
cmeC, suggesting that the gene organization in the cmeABC
operon affects the knockdown efficiency. Similarly, Dryselius
etal.16 reported that theupstream lacZwasmorestrongly inhibited
by PNA thanwere the downstream lacYand lacA proteins in the lac
operon of E. coli. Based on our findings and the previous report, up-
stream genes appear to be most susceptible to PNA-mediated
antisense inhibition in a polycistronic operon.
In addition, the unresponsiveness of CmeC to antisense PNA
might possibly be related to the unique organization of cmeABC
in the operon. The cmeABC genes constitute a polycistronic
operon, in which cmeB and cmeC overlap by 8 bp and the start
codon of cmeC is embedded in the coding region of cmeB.6 The
tight binding of PNA to mRNA disrupts the function of the ribo-
somes and interferes with translation, resulting in gene knock-
down.17 While translation initiation regions are susceptible to
PNA inhibition, PNA binding to a coding region does not result in
knockdown effects in E. coli.13 The start codon and RBS of cmeC
are located in the coding region of cmeB as the start codon of
cmeC is 5 bp upstream of the stop codon of cmeB.6 Although
CmeC-PNAs bind to the translation initiation regions of cmeC,
which is locatedwithin the coding region of cmeB, in this case ribo-
somes translating cmeB may dissociate CmeC-PNAs from mRNA.
This possibility is highbecauseDryseliusetal.16 observeda fullydis-
coordinated reduction in a gfp-DsRed operon that was artificially
constructed placing RBS in an intergenic region between the stop
(a)
(b)
(c)
Figure 2. Target sequences of PNAs against cmeA (a), cmeB (b) and cmeC
(c). The RBSs are underlined, and the start codon is in bold and marked
with a rectangle.
(a)
(b)
(c)
Figure 3. Inhibition efficiency of CmeABC-PNAs. (a) CmeA expression level
visualized by western blotting following treatment with six CmeA-PNAs at
two different concentrations (1 mM and 0.5 mM), as indicated on the left.
CmeA is a glycosylated protein and appears as a doublet band in western
blotting. C, C. jejuni NCTC 11168 without PNA; lanes 1–6, CmeA-PNA1–
CmeA-PNA6, respectively. (b) Changes in the level of CmeB expression
caused by 4 mM CmeB-PNAs. C, C. jejuni NCTC 11168 without PNA; lanes
1–6, CmeB-PNA1–CmeB-PNA6, respectively. (c) Protein levels of CmeC
expression following treatment with 4 mM CmeC-PNAs. C, C. jejuni NCTC
11168 without PNA; lanes 1–6, CmeC-PNA1–CmeC-PNA6, respectively.
An equal amount of the protein sample was used for each lane, and total
proteins were visualized by SDS-PAGE and Coomassie blue staining as a
control in all experiments by using the same protein amount used for
western blotting (data not shown).
(a)
(b)
Figure 4. Concentration-dependent knockdown by CmeA-PNA1 (a) and
CmeB-PNA3 (b). PNA concentrations are indicated at the top.
Oh et al.
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codon of gfp and the start codon ofDsRed. In their artificial operon
construct, antisense PNAs directed at gfp or DsRed exhibited dis-
coordinated inhibitory effects on both upstream and downstream
genes.16
The results of western blotting demonstrated that the RBS is the
major target for the PNA-mediated knockdown of CmeA and CmeB
(Figure3).However, it shouldbenotedthat thesequence inthevicin-
ity around the RBS is also important in determining the knockdown
efficiency of PNA. Although CmeA-PNA2, CmeA-PNA3 and
CmeB-PNA1 harbour the whole sequence of the RBS (Figure 2a
and b), their knockdown efficiency was very low (Figure 3a and b).
These results suggest that targeting the RBS sequence alone is not
sufficient for achieving the best knockdown efficiency and that
both RBS and the sequence in its vicinity play a critical role in deter-
mining the knockdownefficacyof antisense PNA. The start codon of
cmeA, but not of cmeB and cmeC, was susceptible to antisense PNA
(Figure 3). Among the three CmeA-PNAs (4, 5 and 6) harbouring the
cmeAstartcodon,onlyCmeA-PNAs4and5significantly reducedthe
level of CmeA expression, while the antisense effect of CmeA-PNA6
was small (Figure 3a). Similar to the case of targeting the RBS, the
results suggest that both the start codon and its nearby sequence
affect the knockdown efficiency.
In this study, we demonstrated that the target optimization of
antisense PNA for CmeABC knockdown significantly affects the ef-
fectiveness of sensitizing C. jejuni to ciprofloxacin and erythromy-
cin. Although the translation initiation regions are the known
major target for antisense PNA, the knockdown efficiency of anti-
sense PNA is still dependent on other unknown factors. Presum-
ably, the secondary structure of mRNA may be associated with
the inhibitionmechanismofantisensePNA,whichwill beexamined
in future investigations.
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